Mechanism-Centric Approaches for Biomarker Detection and Precision Therapeutics in Cancer

Abstract

Biomarker discovery is at the heart of personalized treatment planning and cancer precision therapeutics, encompassing disease classification and prognosis, prediction of treatment response, and therapeutic targeting. However, many biomarkers represent passenger rather than driver alterations, limiting their utilization as functional units for therapeutic targeting. We suggest that identification of driver biomarkers through mechanism-centric approaches, which take into account upstream and downstream regulatory mechanisms, is fundamental to the discovery of functionally meaningful markers. Here, we examine computational approaches that identify mechanism-centric biomarkers elucidated from gene co-expression networks, regulatory networks (e.g., transcriptional regulation), protein–protein interaction (PPI) networks, and molecular pathways. We discuss their objectives, advantages over gene-centric approaches, and known limitations. Future directions highlight the importance of input and model interpretability, method and data integration, and the role of recently introduced technological advantages, such as single-cell sequencing, which are central for effective biomarker discovery and time-cautious precision therapeutics.

A pan-cancer analysis of copper homeostasis-related gene lipoyltransferase 1: Its potential biological functions and prognosis values

“…Cancers are global health problems, affecting human health and quality of life. According to the statistics from World Health Organization, cancers are the main endangering cause of human life ( Tao et al, 2021 ; Yu and Mitrofanova, 2021 ). Identifying the valuable pan-cancer genes would be crucial to clarify the underlying mechanisms for occurrence and development of different tumors ( He et al, 2021 ; Shi et al, 2021 ).…”

The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia

“…Moreover, there are at least two subclasses of biomarkers, namely prognostic and predictive, based on interaction and differential response to treatment (34,35). In the last twenty years, this broad objective definition was extended, diversified, and subclassified by several authors (36). Nevertheless, the improvements in precision medicine compel the search for new biomarkers.…”

“…Nevertheless, the improvements in precision medicine compel the search for new biomarkers. More recently, we focus on the mechanism-centric approaches for functionally meaningful biomarker selection (36). Unfortunately, identification of a functionally relevant biomarker, specifically for B cell malignancies, requires multifaceted validations, including the generation of mouse models, which makes it meticulous and challenging (20,21,37).…”

DeepInsight-3D architecture for anti-cancer drug response prediction with deep-learning on multi-omics

“…Single-gene biomarkers are now widely and successfully used, most notably BRCA1/BRCA2, ER and PR gene mutations for breast cancers 35 , BRAF and KRAS mutations in colorectal and lung cancers 36 and PD-1/PD-L1 expression for targeting immunotherapy 37 . However, biological processes often arise through complex interactions of different genes, cell types and signaling molecules that are far more challenging to profile, but vital for making further improvements to treatment 38 . Based on these previous results it is now clear that modern machine learning approaches can indeed deliver better predictive performance, but as a trade-off, recovering biological mechanisms that underpin such models still remains challenging.…”